Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib + bendamustine + rituximab vs placebo + bendamustine + rituximab in relapsed/refractory CLL/SLL
2012-000600-15Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing Ibrutinib + bendamustine + rituximab with Placebo + bendamustine + rituximab (2 arms). Primary endpoint: Progression-free survival. Started Jun 2012; status: completed.
02
Drugs
ibrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2012-000600-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000600-15.